Form 8-K · Current Report · Filed 2026-08-18
Twist Bioscience Selected as Evaluator for Anthropic's AI-Driven Protein Design Campaign
On August 18, 2026, Twist Bioscience Corporation announced that it has been selected by Anthropic, PBC as one of its independent evaluators for a multi-arm protein design campaign.
- Filer
- Twist Bioscience Corporation TWST · NASDAQ
- Filed
- Accession
- 0001581280-26-000050
- CIK
- 0001581280
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
This campaign, which utilizes AI models Claude Opus 4.8 and Mythos Preview, aims to rapidly produce and test AI-designed proteins against 15 targets for binding. This partnership highlights Twist Bioscience's role in advancing AI-driven protein research.
Items reported
Reported Item
Market reaction
Close before filing
$124.41
Next session
+14.5%
Since filing
+25.0%
Latest close
$155.56
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from TWST reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, TWST insiders reported 44 Form 4 transactions — net selling of $36.8M.
About Twist Bioscience Corporation
Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.
Never miss another TWST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.